|Day Low/High||3.74 / 3.80|
|52 Wk Low/High||3.04 / 5.45|
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
This biopharma company's Relistor drug should send revenues sharply higher this year.
This biopharma company's Relistor drug should send revenues sharply higher next year.
In our last post we discussed large-cap biotech names that have been beaten up in 2016, are cheap and hopefully will see better days in 2017. Here are a few small-cap biotechs I would keep an eye on in 2017. The following is a quick rundown. Aratana...
These small-caps are woefully undervalued after getting shellacked in October.
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
Don't trade the headline numbers, but cash in on those traders that do.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
The markets look based on the futures like they're heading for slight upwardly tilt in opening trading. Oil is touching $41 a barrel -- its best level of the year even as Russia's central bank is calling crude's recent rally "unsustainable." Of cour...
These biotech/pharma picks could give you a very happy new year.
Adam Feuerstein, senior columnist, explains why the BIO CEO Conference is the next big thing in biotech.